145 related articles for article (PubMed ID: 16368313)
1. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
Natarajan MK; Velianou JL; Turpie AG; Mehta SR; Raco D; Goodhart DM; Afzal R; Ginsberg JS
Am Heart J; 2006 Jan; 151(1):175. PubMed ID: 16368313
[TBL] [Abstract][Full Text] [Related]
2. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
4. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
5. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
Rao SV; Melloni C; Myles-Dimauro S; Broderick S; Kosinski AS; Kleiman NS; Dzavík V; Tanguay JF; Chandna H; Gammon R; Rivera E; Alexander JH; Fier I; Roach J; Becker RC;
Circulation; 2010 Apr; 121(15):1713-21. PubMed ID: 20368520
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
Li WM; Yang XC; Wang LF; Ge YG; Wang HS; Xu L; Ni ZH; Zhang DP
Chin Med J (Engl); 2011 Oct; 124(20):3275-80. PubMed ID: 22088520
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Dudek D; Chyrchel M; Legutko J; Bartuś S; Rzeszutko L; Dubiel JS
Przegl Lek; 2004; 61(12):1301-4. PubMed ID: 15850317
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
10. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
[TBL] [Abstract][Full Text] [Related]
11. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
Cavusoglu E; Lakhani M; Marmur JD
J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
[TBL] [Abstract][Full Text] [Related]
12. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
[TBL] [Abstract][Full Text] [Related]
16. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
17. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
Marmur JD; Bullock-Palmer RP; Poludasu S; Cavusoglu E
J Invasive Cardiol; 2009 Dec; 21(12):653-64. PubMed ID: 19966370
[TBL] [Abstract][Full Text] [Related]
18. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
19. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
Cohen MG; Purdy DA; Rossi JS; Grinfeld LR; Myles SK; Aberle LH; Greenbaum AB; Fry E; Chan MY; Tonkens RM; Zelenkofske S; Alexander JH; Harrington RA; Rusconi CP; Becker RC
Circulation; 2010 Aug; 122(6):614-22. PubMed ID: 20660806
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
